US5935945A
(en)
*
|
1996-10-31 |
1999-08-10 |
Merck & Co., Inc. |
Methods of treating or preventing cardiac arrhythmia
|
TR200002796T2
(tr)
*
|
1998-04-01 |
2000-12-21 |
Nortran Pharmaceuticals Inc. |
Aminosikloheksil eter bileşikleri ve bunların kullanımları.
|
US7507545B2
(en)
|
1999-03-31 |
2009-03-24 |
Cardiome Pharma Corp. |
Ion channel modulating activity method
|
US6531495B1
(en)
|
1999-10-02 |
2003-03-11 |
Aventis Pharma Deutschland Gmbh |
2′-Substituted 1,1′-biphenyl-2-carboxamides, processes for their preparation, their use as medicaments, and pharmaceutical preparations comprising them
|
MY125533A
(en)
|
1999-12-06 |
2006-08-30 |
Bristol Myers Squibb Co |
Heterocyclic dihydropyrimidine compounds
|
US7057053B2
(en)
*
|
2000-10-06 |
2006-06-06 |
Cardiome Pharma Corp. |
Ion channel modulating compounds and uses thereof
|
US7524879B2
(en)
*
|
2000-10-06 |
2009-04-28 |
Cardiome Pharma Corp. |
Ion channel modulating compounds and uses thereof
|
DE10059418A1
(de)
|
2000-11-30 |
2002-06-20 |
Aventis Pharma Gmbh |
Ortho, meta-substituierte Bisarylverbindungen, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament sowie sie enthaltende pharmazeutische Zubereitungen
|
DE10060807A1
(de)
|
2000-12-07 |
2002-06-20 |
Aventis Pharma Gmbh |
Ortho, ortho-substituierte stickstoffhaltige Bisarylverbindungen, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament sowie sie enthaltende pharmazeutische Zubereitungen
|
DE10061876A1
(de)
|
2000-12-12 |
2002-06-20 |
Aventis Pharma Gmbh |
Arylierte Furan- und Thiophencarbonsäureamide, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament sowie sie enthaltende pharmazeutische Zubereitungen
|
DE10121003A1
(de)
|
2001-04-28 |
2002-12-19 |
Aventis Pharma Gmbh |
Anthranilsäureamide, Verfahren zur Herstellung, ihrer Verwendung als Medikament sowie sie enthaltende pharmazeutische Zubereitungen
|
US6783979B2
(en)
|
2001-06-06 |
2004-08-31 |
The Trustees Of Columbia University In The City Of New York Research Foundation Of State University Of New York |
Vectors encoding HCN channels and MiRP1
|
WO2002098287A2
(en)
*
|
2001-06-06 |
2002-12-12 |
The Trustees Of Columbia University In The City Of New York |
A high throughput biological heart rate monitor that is molecularly determined
|
DE10128331A1
(de)
|
2001-06-12 |
2002-12-19 |
Aventis Pharma Gmbh |
Anthranilsäureamide mit Heteroarylsulfonyl-Seitenkette, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltende pharmazeutische Zubereitungen
|
US20090041841A1
(en)
*
|
2003-05-02 |
2009-02-12 |
Cardiome Pharma Corp. |
Controlled release tablet formulations for the prevention of arrhythmias
|
SG167670A1
(en)
*
|
2003-05-02 |
2011-01-28 |
Cardiome Pharma Corp |
Aminocyclohexyl ether compounds and uses thereof
|
US7345086B2
(en)
|
2003-05-02 |
2008-03-18 |
Cardiome Pharma Corp. |
Uses of ion channel modulating compounds
|
GB0315950D0
(en)
|
2003-06-11 |
2003-08-13 |
Xention Discovery Ltd |
Compounds
|
US7674820B2
(en)
*
|
2003-08-07 |
2010-03-09 |
Cardiome Pharma Corp. |
Ion channel modulating activity I
|
US7345087B2
(en)
*
|
2003-10-31 |
2008-03-18 |
Cardiome Pharma Corp. |
Aminocyclohexyl ether compounds and uses thereof
|
DE102004009931A1
(de)
*
|
2004-02-26 |
2005-09-15 |
Aventis Pharma Deutschland Gmbh |
Kv1.5-Blocker zur selektiven Steigerung der Vorhofkontraktilität und Behandlung der Herzinsuffizienz
|
CA2557085A1
(en)
*
|
2004-02-26 |
2005-09-09 |
Merck & Co., Inc. |
Biological assay
|
US8058304B2
(en)
*
|
2004-04-01 |
2011-11-15 |
Cardiome Pharma Corp. |
Merged ion channel modulating compounds and uses thereof
|
US7977373B2
(en)
|
2004-04-01 |
2011-07-12 |
Cardiome Pharma Corp. |
Prodrugs of ion channel modulating compounds and uses thereof
|
US7772232B2
(en)
|
2004-04-15 |
2010-08-10 |
Bristol-Myers Squibb Company |
Quinazolinyl compounds as inhibitors of potassium channel function
|
GB0412986D0
(en)
|
2004-06-10 |
2004-07-14 |
Xention Discovery Ltd |
Compounds
|
ES2483940T3
(es)
*
|
2004-11-08 |
2014-08-08 |
Cardiome Pharma Corp. |
Un nuevo régimen de dosificación para compuestos moduladores del canal iónico para el tratamiento de la fibrilación auricular aguda en un ser humano
|
US7576212B2
(en)
|
2004-12-09 |
2009-08-18 |
Xention Limited |
Thieno[2,3-B] pyridines as potassium channel inhibitors
|
US20060252830A1
(en)
*
|
2005-05-06 |
2006-11-09 |
Brandon Stephen F |
Method for the treatment of magnesium and potassium deficiencies
|
US20060252831A1
(en)
*
|
2005-05-06 |
2006-11-09 |
Christopher Offen |
Method for the treatment of magnesium and potassium deficiencies
|
GB0525164D0
(en)
|
2005-12-09 |
2006-01-18 |
Xention Discovery Ltd |
Compounds
|
GB0815782D0
(en)
|
2008-08-29 |
2008-10-08 |
Xention Ltd |
Novel potassium channel blockers
|
GB0815781D0
(en)
|
2008-08-29 |
2008-10-08 |
Xention Ltd |
Novel potassium channel blockers
|
GB0815784D0
(en)
|
2008-08-29 |
2008-10-08 |
Xention Ltd |
Novel potassium channel blockers
|
GB201105659D0
(en)
|
2011-04-01 |
2011-05-18 |
Xention Ltd |
Compounds
|
NO3175985T3
(ja)
|
2011-07-01 |
2018-04-28 |
|
|
WO2013112932A1
(en)
|
2012-01-27 |
2013-08-01 |
Gilead Sciences, Inc. |
Combination therapies using late sodium ion channel blockers and potassium ion channel blockers
|
EP3206702A1
(en)
*
|
2014-10-16 |
2017-08-23 |
Academisch Medisch Centrum |
Nk3 agonist for use in the treatment of a patient suffering from atrial arrhythmia or fibrillation
|